Stribild Approval History

• FDA approved: Yes (First approved August 27th, 2012)
• Brand name: Stribild
• Generic name: cobicistat, elvitegravir, emtricitabine and tenofovir
• Company: Gilead Sciences, Inc.
• Treatment for: HIV Infection

Stribild (cobicistat, elvitegravir, emtricitabine and tenofovir) is a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults.

FDA Approval History for Stribild

Date	Article
Aug 27, 2012	FDA Approves New Combination Pill Stribild for HIV Treatment
May 11, 2012	FDA Advisory Committee Supports Approval of Gilead's Once-Daily Quad Single Tablet Regimen for HIV
Dec 25, 2011	U.S. FDA Accepts New Drug Application for Gilead's Once-Daily, Single-Tablet Quad HIV Regimen
Oct 28, 2011	Gilead Submits New Drug Application to U.S. FDA for Once-Daily, Single-Tablet "Quad" HIV Regimen

See also...

Stribild (cobicistat, elvitegravir, emtricitabine and tenofovir) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.